HC Wainwright & Co. Reiterates Buy on Verona Pharma, Maintains $32 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Raghuram Selvaraju reiterated a Buy rating on Verona Pharma (NASDAQ:VRNA) and maintained a $32 price target.
June 27, 2023 | 10:51 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Raghuram Selvaraju reiterated a Buy rating on Verona Pharma and maintained a $32 price target.
The reiteration of a Buy rating and maintenance of a $32 price target by HC Wainwright & Co. analyst Raghuram Selvaraju indicates a positive outlook for Verona Pharma's stock in the short term. This news may attract more investors and potentially drive the stock price up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100